Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.Am J Surg Pathol. 2016; 40: 479-489
- STAT6 rabbit monoclonal antibody is a robust diagnostic tool for the distinction of solitary fibrous tumour from its mimics.Pathology. 2014; 46: 389-395
- Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics.Mod Pathol. 2014; 27: 390-395
- WHO classification of Tumours of soft tissue and bone.5th edition. IARC, 2020: 195-197
- Electronic address edsc, Cancer Genome Atlas Research N. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.Cell. 2017; 171: 950-965 e28
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.Nat Genet. 2010; 42: 715-721
- The RB1 gene is the target of chromosome 13 deletions in malignant fibrous histiocytoma.Cancer Res. 2000; 60: 6339-6345
- Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.Am J Pathol. 2010; 177: 2080-2090
- Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant.Am J Surg Pathol. 1996; 20: 391-405
- Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.Ann Surg Oncol. 2016; 23: 818-825
- Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification.J Clin Oncol. 2001; 19: 3045-3050
- Malignant fibrous histiocytoma of the extremity.Cancer. 1999; 85: 1765-1772
- Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy.Int J Radiat Oncol Biol Phys. 2018; 102: 399-406
- Prognostic factors and outcomes of patients with myxofibrosarcoma.Ann Surg Oncol. 2013; 20: 80-86
- Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution.Ann Surg Oncol. 2011; 18: 720-725
- The enigma of myxofibrosarcoma of the extremity.Cancer. 2012; 118: 518-527
- Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma.Int J Radiat Oncol Biol Phys. 2012; 82: 361-367
- Myxofibrosarcoma: prevalence and diagnostic value of the "tail sign" on magnetic resonance imaging.Skeletal Radiol. 2013; 42: 809-818
- Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease.AJR Am J roentgenology. 2007; 188: W193-W198
- Temporizing Wound VAC Dressing Until Final Negative Margins are Achieved Reduces Myxofibrosarcoma Local Recurrence.Ann Surg Oncol. 2021; https://doi.org/10.1245/s10434-021-10242-4
- Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas.Ann Surg. 2007; 246: 675-681
- A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation.Ann Surg. 2012; 255: 343-347
- A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.Cancer. 2008; 113: 573-581
- The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.Eur J Cancer. 2019; 109: 51-60
- Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis.Lancet Oncol. 2016; 17: 671-680
- Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.Lancet Oncol. 2017; 18: 812-822
- Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.Cancer. 2022; 128: 85-93
- Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2018; 29: iv51-iv67
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.Lancet Oncol. 2014; 15: 415-423
- Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002.J Clin Oncol. 2007; 25: 2755-2763
- Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.Lancet Oncol. 2017; 18: 1397-1410
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet. 2012; 379: 1879-1886
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.Lancet Oncol. 2017; 18: 1493-1501
- Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.J Clin Oncol. 2019; 37: 11015
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.Lancet Oncol. 2018; 19: 416-426
- Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).J Clin Oncol. 2020; 38: 11505
- Integrin-alpha10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.Cancer Discov. 2016; 6: 1148-1165
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
